Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- PFIZER TO CUT DOWN 2,200 JOB
- AsiaInfo Services 12-04-2006 Pfizer to Cut down 2,200 Job SHANGHAI, Dec 04, 2006 SinoCast via COMTEX -- Pfizer Inc., the world's largest drugmaker, said on November 29 that it will axe 2,200 employees in its sales department in US, accounting ...
- Research articles 2006-12-04
- Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining
- A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing. At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below. ...
- Blog posts 2009-02-24
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- Ranking of 20 Drug Companies Shows Sales Force Effectiveness Reaching Plateau
- A ranking of 20 drug companies by sales and marketing productivity shows that 10 companies saw upward trends in effectiveness in Q2 2009. Last quarter, 13 companies had upward trends. The numbers indicate that companies have started to reach a plateau in their efforts to wring more revenues out of...
- Blog posts 2009-08-07
- GSK and Others See Massachusetts Showdown Over Drug-Marketing Reform
- There are two ideas floating in the world of politics to curb the way drug companies give doctors gifts and often biased information. One of them is a good idea, and one of them is a bad idea. Drug companies -- such as GlaxoSmithKline -- have chosen...
- Blog posts 2008-08-08
- Ranking of 20 Drug Companies by Sales Force Effectiveness Shows Improvement in Q1
- A ranking of 20 drug companies on sales and marketing productivity shows upward trends in effectiveness in Q1 2009. At the top of the table is AIDS drug specialist Gilead. At the bottom of the table is vanity pharma play Medicis. by Jim Edwards
- Blog posts 2009-05-14
- Pharma Roundup: Schering-Plough Surveys Investors, Wyeth Defended, and More
- Schering-Plough shareholders to have say on executive compensation, U.S. drug sales predictions lowered, McCain and Obama both promise hard line on Big Pharma. Also: two lawyers condemn unfounded anti-Wyeth opinions. by John Maas
- Blog posts 2008-10-29
Additional Resources
- Our Favorite Drug Company Conference Call Tap Dancers
- Drug company conference calls with Wall Street are often dull or baffling -- a fast tide of numbers and facts extracted by spreadsheet jocks. But they're often the only chance we have to hear CEOs and other senior execs talking without the benefit of prepared remarks. Every once in while...
- Blog posts 2008-11-13
- The 10 Weirdest Drug Stories of the Month
- A vaccine for smoking! Power hungry Eli Lilly execs! Flu shots from caterpillars! It all happened in November 2009. Biogen CEO pay = $148 million for 6 years Letter to the SEC: "CEO, James Mullen, has sold more than $85 million of stock, which we estimate...
- Blog posts 2009-12-02
- Report: Company-funded studies of Pfizer epilepsy drug misleading | News from The Post-Standard -
- Report: Company-funded studies of Pfizer epilepsy drug misleading By The Associated Press November 11, 2009, 8:16PM Mark Lennihan / The Associated Press, 2009The Pfizer world headquarters in New York. Analysis of a dozen published studies testing possible new uses for a Pfizer Inc. epilepsy drug...
- News items 2009-11-11
- The 10 Weirdest Drug Stories of the Month
- Another page has been torn off the calendar, and that means it's time to open up Big Pharma's vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug...
- Blog posts 2008-10-01
- Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
- The FDA delivered to Cephalon a letter yesterday saying it would not approve expanded indications for its pain drug Fentora until the company gave it more information on how it would prevent the drug from being abused. Even though the Fentora situation is fixable, it's just the sort of headache...
- Blog posts 2008-09-16
- The 10 Weirdest Drug Stories of the Month
- We're a little late, but here are the 10 weirdest drug stories that popped up onto BNET's radar during March. They were all too small to write about, but too strange to ignore: Did GlaxoSmithKline unwittingly reveal that Wynnona Judd's latest album has been heavily photoshopped? ...
- Blog posts 2009-04-03
- Abbott under kickback probe over Depakote sales -
- Abbott Laboratories this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat bipolar disorder and epilepsy, are under federal investigation. The U.S. Department of Justice , through the U.S. Attorney for the Western District of Virginia...
- News items 2009-11-06
- FDA scrutiny adds to woes at Akorn specialty drug firm; Stock plunges in wake of earnings disappointment.(Brief Article)
- Akorn Inc. has come under regulatory fire just as sales growth is slowing for the first time in years at the Buffalo Grove-based specialty drug company. In October, the U.S. Food and Drug Administration FDA cited Akorn for failing to comply with Akorn...
- Research articles 2000-11-06
- Gilead Q1: Company Is Recession Resistant But Not Lawsuit Resistant
- Yet another gravity-defying quarter at Gilead: Revenues were up 22 percent to $1.5 billion; net income was up 21 percent to $589 million. But same bad news lurks behind the numbers in the form of a shareholder lawsuit that was given the go-ahead by the US Supreme Court a few...
- Blog posts 2009-04-22
- Roche Fraud Case Exposes Corruption Encouraged by Drug Pricing Politics
- Roche has emerged as both victim and enabler in a big corruption case whose basis was the arcane pricing policies of U.S. drugs. In the case, two brothers who ran a medical supplies company were sentenced to nine years in prison for skimming contracts and avoiding taxes. ...
- Blog posts 2009-01-15
- J&J and Risperdal: New Claims of Kickbacks and Fraudulent Marketing
- The news on Risperdal continues to get worse for Johnson & Johnson and its antipsychotic unit, Janssen Pharmaceuticals. Texas officials filed suit against the company alleging Medicaid fraud, kickbacks and improper marketing of the drug to children and the poor in that state. J&J denies the claims. ...
- Blog posts 2008-12-17
- FDA to Allow "Off-Label" Unapproved Drug Promotion
- The FDA has "finalized" guidelines allowing drug companies to promote drugs for unapproved ("off-label") uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses. Drug companies and their right-wing stalking horse, the Washington Legal Foundation, have been pushing for this move for years....
- Blog posts 2009-01-13
- BMS Sales Increase Masks Looming Patent Cliff Disaster
- Bristol-Myers Squibb is dependent for half its revenues on just three drugs, and those brands will all be generic by 2012, the NYT reports. The article asks whether BMS can survive on its own or be acquired, possibly by Sanofi Aventis: Of Bristol-Myers’s $4.5 billion in drug...
- Blog posts 2009-01-28
- << Previous
- page 1 of 1
- Next >>
Presented by American Express